Five Plaintiffs Join Illinois Yaz MDL Alleging Various Side Effects

A new lawsuit was filed against manufacturer Bayer for their birth control medications Yaz and Yasmin and added to the multidistrict litigation (MDL) located in the U.S. District Court for the Southern District of Illinois.

A new lawsuit was filed against manufacturer Bayer for their birth control medications Yaz and Yasmin and added to the multidistrict litigation (MDL) located in the U.S. District Court for the Southern District of Illinois.

The Yaz lawsuit was filed by attorneys on behalf of multiple plaintiffs, all of whom suffered side effects from the medication including heart attack, gallbladder problems, stroke, pulmonary embolism (PE), and blood clots. It is alleged in the filing that the hormones in Yaz and Yasmin contributed to the injuries suffered by the plaintiffs.

The causes of action in the lawsuit include negligence and strict liability. Bayer, according to the filing, knew or should have known of the risks of Yaz and Yasmin, but didn’t inform medical professionals or patients of the potential dangers.

Plaintiffs claim stroke, blood clots, heart and gallbladder problems from Yaz and Yasmin

The lawsuit consists of five plaintiffs who suffered from a variety of medical issues they claim were connected to their use of Yaz and Yasmin. One plaintiff, Eyvette Johnson, developed blood clots following her use of the pills for over a year. The estate of Stephanie Lyons is suing Bayer because Lyons died after having a stroke. She used Yaz or Yasmin for slightly over a month.

The other plaintiffs in the case—Kayla Anne Mies, Glenda Thomas, and Anita Luckenbaugh—had various Yaz side effects.

Luckenbaugh took the drugs for over a year and was diagnosed with PE and deep vein thrombosis (DVT). Mies took the pills for six years and eventually developed severe complications with her gallbladder which eventually required its removal. Thomas used the pills for four months and suffered from a heart blockage.

According to the plaintiffs, if they knew of the possibility of these side effects, they would not have chosen to take them. They seek compensation for past, present and future medical expenses as well as diminished quality of life, mental anguish, and pain and suffering.

Clinical studies show dangers of Yaz and Yasmin

Yaz and Yasmin were marketed by Bayer as superior alternatives to other forms of birth control. It was claimed by the manufacturer that not only did they prevent pregnancy, but they also could be used to treat premenstrual syndrome (PMS) and reduce acne.

A warning letter was issued by the Food and Drug Administration (FDA) that indicated clinical studies had contradicted such assertions of these birth control medications of being safer or more beneficial in comparison to other contraceptives. The studies actually revealed dangers with Yaz and Yasmin such as users being at higher risk for for DVT, heart attack and other complications.

The FDA didn’t approve of Bayer marketing the drugs for any reason other than to function as birth control devices. In addition, the advertising didn’t list the possible side effects when using Yaz and Yasmin.

New progestin in Yaz and Yasmin can increase risks

The FDA approved Yaz in 2001 and Yasmin in 2006. The ingredients include estrogen and progestin to prevent pregnancy. The estrogen is known as ethynol estradiol. The progestin, drospirenone, is new and prior to the approval of Yaz, had never been marketed in the U.S. Aside from Yaz and Yasmin, the only birth control medication that uses this progestin is Ocella, the generic form of Yaz and Yasmin.

Upon the introduction of oral contraceptives onto the market, researchers discovered that estrogen was linked to an increased risk of blood clots, strokes, and heart attacks.

But when a lower amount of estrogen was combined with certain progestins, the risk of dangerous side effects for users of these pills was reduced. Clinical studies designed to assess drospirenone’s safety discovered that the progestin isn’t as effective at lowering the risk of blood clots as other birth control pills.

Drospirenone was also found to increase the risk of hyperkalemia. Hyperkalemia occurs when the potassium level in the blood rises to the point that it leads to PE, stroke, or heart attack. Complications with the kidneys, liver and gallbladder are also possible.

Bayer accused of withholding studies showing risks of Yaz and Yasmin

Between 2004 and 2008, more than 50 reports of fatalities of patients who used Yaz and Yasmin were reported to the FDA. Some of the causes of death included strokes, PE, and heart attacks. The former head of the FDA stated that manufacturer Bayer withheld findings from a study that indicated women had a higher risk of suffering from PE and DVT when they used Yaz and Yasmin.The Yaz lawsuit was filed by attorneys on behalf of multiple plaintiffs, all of whom suffered side effects from the medication including heart attack, gallbladder problems, stroke, pulmonary embolism (PE), and blood clots. It is alleged in the filing that the hormones in Yaz and Yasmin contributed to the injuries suffered by the plaintiffs.

The causes of action in the lawsuit include negligence and strict liability. Bayer, according to the filing, knew or should have known of the risks of Yaz and Yasmin, but didn’t inform medical professionals or patients of the potential dangers.

Plaintiffs claim stroke, blood clots, heart and gallbladder problems from Yaz and Yasmin

The lawsuit consists of five plaintiffs who suffered from a variety of medical issues they claim were connected to their use of Yaz and Yasmin. One plaintiff, Eyvette Johnson, developed blood clots following her use of the pills for over a year. The estate of Stephanie Lyons is suing Bayer because Lyons died after having a stroke. She used Yaz or Yasmin for slightly over a month.

The other plaintiffs in the case—Kayla Anne Mies, Glenda Thomas, and Anita Luckenbaugh—had various Yaz side effects.

Luckenbaugh took the drugs for over a year and was diagnosed with PE and deep vein thrombosis (DVT). Mies took the pills for six years and eventually developed severe complications with her gallbladder which eventually required its removal. Thomas used the pills for four months and suffered from a heart blockage.

According to the plaintiffs, if they knew of the possibility of these side effects, they would not have chosen to take them. They seek compensation for past, present and future medical expenses as well as diminished quality of life, mental anguish, and pain and suffering.

Clinical studies show dangers of Yaz and Yasmin

Yaz and Yasmin were marketed by Bayer as superior alternatives to other forms of birth control. It was claimed by the manufacturer that not only did they prevent pregnancy, but they also could be used to treat premenstrual syndrome (PMS) and reduce acne.

A warning letter was issued by the Food and Drug Administration (FDA) that indicated clinical studies had contradicted such assertions of these birth control medications of being safer or more beneficial in comparison to other contraceptives. The studies actually revealed dangers with Yaz and Yasmin such as users being at higher risk for for DVT, heart attack and other complications.

The FDA didn’t approve of Bayer marketing the drugs for any reason other than to function as birth control devices. In addition, the advertising didn’t list the possible side effects when using Yaz and Yasmin.

New progestin in Yaz and Yasmin can increase risks

The FDA approved Yaz in 2001 and Yasmin in 2006. The ingredients include estrogen and progestin to prevent pregnancy. The estrogen is known as ethynol estradiol. The progestin, drospirenone, is new and prior to the approval of Yaz, had never been marketed in the U.S. Aside from Yaz and Yasmin, the only birth control medication that uses this progestin is Ocella, the generic form of Yaz and Yasmin.

Upon the introduction of oral contraceptives onto the market, researchers discovered that estrogen was linked to an increased risk of blood clots, strokes, and heart attacks.

But when a lower amount of estrogen was combined with certain progestins, the risk of dangerous side effects for users of these pills was reduced. Clinical studies designed to assess drospirenone’s safety discovered that the progestin isn’t as effective at lowering the risk of blood clots as other birth control pills.

Drospirenone was also found to increase the risk of hyperkalemia. Hyperkalemia occurs when the potassium level in the blood rises to the point that it leads to PE, stroke, or heart attack. Complications with the kidneys, liver and gallbladder are also possible.

[SmartLink yazlawsuit]

Bayer accused of withholding studies showing risks of Yaz and Yasmin

Between 2004 and 2008, more than 50 reports of fatalities of patients who used Yaz and Yasmin were reported to the FDA. Some of the causes of death included strokes, PE, and heart attacks. The former head of the FDA stated that manufacturer Bayer withheld findings from a study that indicated women had a higher risk of suffering from PE and DVT when they used Yaz and Yasmin.